Business & Economics
Oncology
100%
Cost-effectiveness
98%
Cost-effectiveness Ratio
70%
Progression
69%
Incremental Cost
35%
Costs
26%
Marginal Cost
26%
Drugs
17%
Quality-adjusted Life Years
14%
End of Life
6%
Health Care Costs
5%
Weighting
5%
Excellence
4%
Costs and Benefits
4%
Incremental
4%
Health
3%
Modeling
3%
Evaluation
2%
Alternatives
2%
Factors
1%
Medicine & Life Sciences
Cost-Benefit Analysis
60%
Costs and Cost Analysis
34%
Drug Costs
18%
Economic Models
14%
Quality-Adjusted Life Years
11%
Technology
9%
National Institutes of Health (U.S.)
5%
Health Care Costs
4%
Delivery of Health Care
3%
Pharmaceutical Preparations
2%
Social Sciences
costs
39%
marginal costs
21%
drug
7%
economic model
6%
weighting
3%
new technology
2%
health care
2%
health
1%
evaluation
1%